We are a clinical-stage biopharmaceutical company focused on bringing new and better treatment options to patients with coronary artery disease (CAD), with the aim of preventing heart attacks.
Abcentra’s core technology allows for targeting of oxidized low-density lipoprotein (OxLDL), a novel and highly specific approach to quelling coronary inflammation, which has the potential to maximize efficacy and safety compared to other anti-inflammatory therapies for CAD.
The Company’s clinical-stage product, Orticumab, is a first-in-class monoclonal antibody against oxidized LDL (OxLDL), the critical driver of atherosclerotic disease and heart attack. Abcentra is developing Orticumab for secondary prevention of cardiac events after an acute coronary syndrome (ACS), with further plans to expand use of orticumab into primary prevention in CAD patients with coronary inflammation.
Company Details
- Employees
- 15
- Founded
- -
- Address
- 1925 Century Park E,
- Phone
- +1 424 263 6364
- in****@****tra.com
- Industry
- Biotechnology
- Website
- abcentra.com
- Keywords
- Research & Development, Immunotherapies, Cardiovascular, Therapeutic Antibodies, Dermatology, plaque psoriasis, oncology, lipoprotein(a), inflammation, atherosclerosis.
- HQ
- Los Angeles, California
Abcentra Questions
Abcentra's helpline number is +1 424 263 6364
Abcentra's website is abcentra.com
Abcentra's LinkedIn profile is https://www.linkedin.com/company/abcentra
Abcentra has
15 employees.
View email and phone details for 15
employees at Abcentra.
Abcentra's industry is
Biotechnology
Abcentra's top competitors are
Synthekine,
Atengen, Inc.,
Immix Biopharma (Nasdaq: Immx),
Abbvie,
Nexcella, Inc.,
Kairos Pharma Ltd. (Nyse: Kapa),
Horizon,
Alnylam Pharmaceuticals,
Hcw Biologics,
Abcuro, Inc.
Abcentra's support email address is info@abcentra.com
Abcentra's categories are Biotechnology
Abcentra's founding year is 2006
